Ozempic
Ozempic (semaglutide) is a GLP-1 receptor agonist injectable prescription medicine used with diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce risks of major cardiovascular events, stroke, heart attack, death, kidney disease progression, and end-stage kidney disease in those with known heart disease or chronic kidney disease.
Brief glance
Ozempic is a branded drug product manufactured by Novo Nordisk. Its active substance is Semaglutide. The linked substance is commonly grouped under “Weight Loss” as a primary outcome. FDA status: Approved. First FDA approval on record: Dec 2017. It is not currently flagged on our shortage list.
| Phase | Days | Dosage | Frequency |
|---|---|---|---|
| titration | 1 – 28 | 0.25 mg | Every 7 days |
| maintenance | 29+ | 0.5 mg | Every 7 days |
Follows prescribing guidance issued for this product. Not medical advice — consult your healthcare professional before starting, adjusting, or stopping any medication.
Overview
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events, such as heart attack, stroke, or death, in adults with type 2 diabetes and known heart disease, and to reduce the risk of kidney disease worsening, kidney failure, or cardiovascular death in those with type 2 diabetes and chronic kidney disease. Administered as a once-weekly subcutaneous injection in doses of 0.5 mg, 1 mg, or 2 mg.
Ozempic (semaglutide) is a prescription injectable medication classified as a glucagon-like peptide-1 (GLP-1) receptor agonist. Administered once weekly via subcutaneous injection using a prefilled pen in strengths of 0.5 mg, 1 mg, or 2 mg, it is FDA-approved, along with diet and exercise, to improve blood sugar control in adults with type 2 diabetes. It is also indicated to reduce the risk of major cardiovascular events, such as heart attack, stroke, or death, in adults with type 2 diabetes and known heart disease, as well as to lower the risk of kidney disease progression, end-stage kidney disease, and cardiovascular death in those with type 2 diabetes and chronic kidney disease. Ozempic may be used alone or combined with other diabetes medications, but not with insulin in the same injection.
Benefits
Ozempic is indicated, along with diet and exercise, to improve glycemic control in adults with type 2 diabetes, achieving significant reductions in hemoglobin A1c levels and better fasting and postprandial blood sugar control as shown in clinical trials like SUSTAIN 1.1,2 It reduces the risk of major adverse cardiovascular events, including heart attack, stroke, and cardiovascular death, in adults with type 2 diabetes and established cardiovascular disease.1,2 Additionally, it lowers the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, supported by evidence from the FLOW trial.1,2 As a GLP-1 receptor agonist, it also supports weight loss and maintenance through appetite reduction and increased satiety.1,3
Side effects
The most common side effects of Ozempic (semaglutide) include nausea, vomiting, diarrhea, abdominal pain, and constipation, which are primarily gastrointestinal and often improve with gradual dose escalation.4,5 Less frequent mild effects may involve burping, gas, bloating, fatigue, headache, decreased appetite, and injection site reactions.4,6,7 Rare but serious adverse effects reported include pancreatitis, gallbladder disease such as gallstones, acute kidney injury, gastroparesis, intestinal blockage, severe hypoglycemia, vision changes, and serious allergic reactions manifesting as swelling, breathing difficulties, or rapid heartbeat.4,5,6 Key safety considerations encompass monitoring for these risks, especially in patients with a history of pancreatitis or thyroid cancer (due to rodent study findings), avoiding use in those with personal/family medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and promptly seeking medical help for persistent or severe symptoms.4,5,6 Hypoglycemia risk increases when combined with insulin or sulfonylureas, necessitating blood glucose monitoring.4,6
Mechanisms of action
Ozempic (semaglutide) is a GLP-1 receptor agonist that selectively binds to and activates GLP-1 receptors, mimicking the action of native glucagon-like peptide-1 (GLP-1).8,9,10 This activation stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner while suppressing glucagon secretion from alpha cells, thereby lowering fasting and postprandial blood glucose levels.8,11,12 It also causes a minor delay in gastric emptying, reducing the postprandial rate of glucose appearance in circulation.8,12 Structural modifications provide 94% homology to human GLP-1, along with protection from DPP-4 degradation and reduced renal clearance, resulting in an elimination half-life of approximately 7 days for once-weekly dosing.8,9,12